G. Stone

发表

Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014

K. Kazmierczak, J. Karlowsky, D. Sahm, 2016, Antimicrobial Agents and Chemotherapy.

The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus.

Li Basuino, G. Sensabaugh, F. DeLeo, 2008, The Journal of infectious diseases.

In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019

K. Kazmierczak, J. Karlowsky, D. Sahm, 2021, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015

K. Kazmierczak, J. Karlowsky, D. Sahm, 2018, Antimicrobial Agents and Chemotherapy.

Nasal colonization by methicillin-resistant coagulase-negative staphylococcus in community skilled nursing facility patients.

T. Cesario, G. Stone, L. Thrupp, 2000, American journal of infection control.

Detection of Salmonella serovars from clinical samples by enrichment broth cultivation-PCR procedure

S. McVey, M. Hays, M. Chengappa, 1994, Journal of clinical microbiology.

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia

T. Riccobene, Jianguo Li, I. Critchley, 2019, Antimicrobial Agents and Chemotherapy.

Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus.

N. Soni, R. Flamm, G. Stone, 2002, Diagnostic microbiology and infectious disease.

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

T. Riccobene, I. Critchley, Shampa Das, 2018, Antimicrobial Agents and Chemotherapy.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa

Ronald N. Jones, M. Huband, P. Rhomberg, 2018, Journal of Clinical Microbiology.

A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing

M. Huband, P. Bradford, G. Stone, 2018, Antimicrobial Agents and Chemotherapy.

Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.

T. Welte, G. Stone, J. Hammond, 2019, International journal of antimicrobial agents.

PCR-Oligonucleotide Ligation Assay for Detection of Point Mutations Associated with Quinolone Resistance in Streptococcus pneumoniae

R. Flamm, G. Stone, M. Bui, 2003, Antimicrobial Agents and Chemotherapy.

A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori

D. Graham, J. Versalovic, D. Shortridge, 1997, Antimicrobial agents and chemotherapy.

Identification of a 23S rRNA Gene Mutation in Clarithromycin‐Resistant Helicobacter pylori

J. Versalovic, D. Shortridge, R. Flamm, 1996, Helicobacter.

Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program

T. Riccobene, G. Stone, W.-J. Chang, 2022, Antimicrobial agents and chemotherapy.

Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia

T. Riccobene, G. Stone, T. Carrothers, 2021, Pediatric Drugs.

In vitro activity of ceftazidime/avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from Middle Eastern and African countries: ATLAS global surveillance programme 2015–18

J. Karlowsky, D. Sahm, S. Bouchillon, 2021, JAC-antimicrobial resistance.

Activity of ceftaroline against pathogens associated with community-acquired pneumonia collected as part of the AWARE surveillance program, 2015-2016.

I. Bae, G. Stone, 2019, Diagnostic microbiology and infectious disease.

Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.

J. Bradley, D. Wajsbrot, K. Cheng, 2019, The Pediatric infectious disease journal.

Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Enterobacteriaceae, 2012-2016.

G. Stone, E. Ramalheira, 2019, Journal of global antimicrobial resistance.

In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections

P. Bradford, G. Stone, P. Newell, 2018, Antimicrobial Agents and Chemotherapy.

Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014

K. Kazmierczak, M. Hackel, D. Hoban, 2016, Antimicrobial Agents and Chemotherapy.

Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program

Y. Carmeli, J. Mazuski, A. Torres, 2021, Infectious Diseases and Therapy.

Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials

J. Yan, M. Dryden, G. Stone, 2021, Infectious Diseases and Therapy.

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.

Binh Giang Tran, X. Qin, J. Chow, 2017, International journal of antimicrobial agents.

Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.

T. Dougherty, Liang Zhao, C. Eyermann, 2014, Bioorganic & medicinal chemistry.

A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators

James G. Wright, A. Cristinacce, L. Mcfadyen, 2019, Infectious Diseases and Therapy.

Combined PCR-oligonucleotide ligation assay for rapid detection of Salmonella serovars

S. McVey, M. Hays, M. Chengappa, 1995, Journal of clinical microbiology.

The primary pharmacology of ceftazidime/avibactam: in vitro translational biology.

P. Bradford, G. Stone, W. Nichols, 2022, The Journal of antimicrobial chemotherapy.

Prevalence of mcr-type genes among colistin-resistant Enterobacteriaceae collected in 2014-2016 as part of the INFORM global surveillance program

K. Kazmierczak, D. Sahm, M. Wise, 2018, PloS one.

Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17.

K. Kazmierczak, D. Sahm, G. Stone, 2020, The Journal of antimicrobial chemotherapy.

In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012–15

K. Kazmierczak, D. Sahm, G. Stone, 2018, The Journal of antimicrobial chemotherapy.

Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK)

N. Woodford, F. Davies, H. H. Wu, 2018, The Journal of antimicrobial chemotherapy.

Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis

T. Riccobene, P. Chan, J. Bradley, 2020, The Pediatric infectious disease journal.

Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.

Bryan M. Li, T. Dougherty, R. Obach, 2009, Journal of medicinal chemistry.

In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015 to 2017.

H. Seifert, C. Nord, G. Stone, 2020, International journal of antimicrobial agents.

In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15

K. Kazmierczak, D. Sahm, G. Stone, 2018, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015

K. Kazmierczak, J. Karlowsky, D. Sahm, 2018, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity of ceftazidime-avibactam and comparators against levofloxacin-resistant Escherichia coli collected from four geographic regions, 2012–2018

M. Hackel, G. Stone, 2021, Annals of clinical microbiology and antimicrobials.

Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value

Ronald N. Jones, H. Sader, R. Flamm, 2014, Journal of chemotherapy.

PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial.

D. Shortridge, R. Flamm, G. Stone, 1997, The Journal of antimicrobial chemotherapy.

Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism

J. Versalovic, D. Graham, R. Flamm, 1997, Journal of clinical microbiology.

In vitro activity of ceftazidime–avibactam and comparators against Gram-negative bacterial isolates collected in the Asia–Pacific region as part of the INFORM program (2015–2017)

W. Ko, G. Stone, 2020, Annals of Clinical Microbiology and Antimicrobials.

Detection of Salmonella typhimurium from rectal swabs of experimentally infected beagles by short cultivation and PCR-hybridization

S. McVey, R. Curtiss, M. Hays, 1995, Journal of clinical microbiology.

Synthesis and antibacterial activity of 6-O-arylbutynyl ketolides with improved activity against some key erythromycin-resistant pathogens.

G. Stone, Melissa M. Daly, E. Englund, 2003, Journal of medicinal chemistry.

Assessment of the in vitro activity of ceftazidime-avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance program (2015-2017).

G. Rossolini, G. Stone, 2020, International journal of antimicrobial agents.

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme

J. Chow, G. Stone, L. Gasink, 2018, The Journal of antimicrobial chemotherapy.

Ceftazidime-avibactam in ceftazidime-resistant infections.

Y. Carmeli, J. Armstrong, G. Stone, 2016, The Lancet. Infectious diseases.

The discovery and structure-activity relationships leading to CE-156811, a difluorophenyl cyclopropyl fluoroether: a novel potent antibacterial analog derived from hygromycin A.

S. J. Brickner, J. Liras, G. Stone, 2011, Bioorganic & medicinal chemistry letters.

In Vitro Antibacterial Activity of CE-156811, a Novel Analog Derived from Hygromycin A

M. Huband, S. J. Brickner, G. Stone, 2008, Antimicrobial Agents and Chemotherapy.

Antibiotic Drug Development: Moving Forward into the Clinic

J. Ambler, G. Stone, 2012 .

Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.

M. Gowravaram, G. Basarab, V. Galullo, 2014, Journal of medicinal chemistry.

Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance.

D. Graham, J. Versalovic, M. Dore, 1997, The Journal of antimicrobial chemotherapy.

Conjunctival microbial flora of clinically normal pigs.

M. Chengappa, D. P. Rogers, G. Stone, 1994, American journal of veterinary research.

In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015–17)

K. Kazmierczak, G. Stone, I. Spiliopoulou, 2019, The Journal of antimicrobial chemotherapy.

Application of Polymerase Chain Reaction for the Correlation of Salmonella Serovars Recovered from Greyhound Feces with Their Diet

S. McVey, M. Chengappa, G. Stone, 1993, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

The primary pharmacology of ceftazidime/avibactam: resistance in vitro.

P. Bradford, G. Stone, W. Nichols, 2023, The Journal of antimicrobial chemotherapy.

Molecular Characterization of Clinical Isolates of Enterobacterales with Elevated MIC Values for Aztreonam-Avibactam from the INFORM Global Surveillance Study, 2012-2017.

K. Kazmierczak, D. Sahm, F. Arhin, 2021, Journal of global antimicrobial resistance.

In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015

K. Kazmierczak, P. Bradford, D. Sahm, 2018, Antimicrobial Agents and Chemotherapy.

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.

M. Kollef, J. Timsit, N. Zhong, 2017, The Lancet. Infectious diseases.

Immunogenicity of chi4127 phoP- Salmonella enterica serovar Typhimurium in dogs.

D. S. McVey, R. Curtiss, M. Chengappa, 2002, Vaccine.

Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa causing infection in Africa and the Middle East: a surveillance study from the ATLAS programme (2018–20)

J. Karlowsky, D. Sahm, S. Bouchillon, 2022, JAC-antimicrobial resistance.

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

M. Huband, A. Marfat, J. Driscoll, 2013, Bioorganic & medicinal chemistry letters.

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.

Y. Carmeli, P. Laud, J. Armstrong, 2016, The Lancet. Infectious diseases.

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

J. Mazuski, J. Pachl, J. Armstrong, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017

K. Kazmierczak, J. Karlowsky, D. Sahm, 2021, Antimicrobial agents and chemotherapy.

In vitro activity of aztreonam-avibactam (ATM-AVI) against a global collection of Klebsiella pneumoniae, collected from defined culture sources, in 2016 and 2017.

S. Esposito, G. Stone, J. Papaparaskevas, 2020, Journal of global antimicrobial resistance.

In vitro activity of ceftazidime/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017

G. Stone, A. Ponce-de-León, 2020, The Journal of antimicrobial chemotherapy.

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

Paul Newell, J. Sobel, F. Wagenlehner, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

NBTI 5463 Is a Novel Bacterial Type II Topoisomerase Inhibitor with Activity against Gram-Negative Bacteria and In Vivo Efficacy

T. Dougherty, D. Ehmann, M. Cronin, 2014, Antimicrobial Agents and Chemotherapy.

NBTI 5463 Is a Novel Bacterial Type II Topoisomerase Inhibitor with Activity against Gram-Negative Bacteria and In Vivo Efficacy

T. Dougherty, D. Ehmann, M. Cronin, 2014, Antimicrobial Agents and Chemotherapy.

Development of EUCAST zone diameter breakpoints and quality control criteria for ceftazidime-avibactam 10-4 μg

L. Koeth, G. Kahlmeter, E. Matuschek, 2018, European Journal of Clinical Microbiology & Infectious Diseases.

The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD).

P. Bradford, G. Stone, W. Nichols, 2022, The Journal of antimicrobial chemotherapy.

Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets

Mariana Castanheira, M. Castanheira, P. Bradford, 2017, Antimicrobial Agents and Chemotherapy.

In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections.

D. Piérard, G. Stone, 2021, Journal of global antimicrobial resistance.

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections

Diansong Zhou, J. Yan, Jianguo Li, 2018, The Journal of antimicrobial chemotherapy.

Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.

M. Castanheira, P. Bradford, R. Mendes, 2018, International journal of antimicrobial agents.

β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates

Ronald N. Jones, M. Castanheira, R. Mendes, 2015, Antimicrobial Agents and Chemotherapy.

Design, synthesis and structure-activity relationships of 6-O-arylpropargyl diazalides with potent activity against multidrug-resistant Streptococcus pneumoniae.

N. Soni, R. Clark, K. Marsh, 2005, Bioorganic & Medicinal Chemistry Letters.

Synthesis and antibacterial activity of novel bifunctional macrolides.

I. Akritopoulou‐Zanze, S. Djurić, G. Stone, 2004, Bioorganic & medicinal chemistry letters.

Design, Synthesis and Structure—Activity Relationships of 6-O-Arylpropargyl Diazalides with Potent Activity Against Multidrug-Resistant Streptococcus Pneumoniae.

N. Soni, R. Clark, K. Marsh, 2005 .

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa

G. Rossolini, G. Daikos, P. Irani, 2021, Antibiotics.

In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens

P. Bradford, G. Stone, P. Newell, 2016, Antimicrobial Agents and Chemotherapy.

Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections.

E. Urbán, G. Stone, 2019, Clinical Microbiology and Infection.

In Vitro Activity of Ceftaroline against Bacterial Pathogens Isolated from Patients with Skin and Soft Tissue and Respiratory Tract Infections in the Middle East and Africa: AWARE Global Surveillance Program 2015-2018.

M. Hackel, J. Karlowsky, D. Sahm, 2020, Journal of global antimicrobial resistance.

The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study

Á. Soriano, M. Bassetti, Marisa Sánchez, 2023, Infectious Diseases and Therapy.

In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial

P. Bradford, J. Chow, G. Stone, 2020, Antimicrobial Agents and Chemotherapy.

Efficacy In Vivo against Gram-Negative Bacteria and Topoisomerase Inhibitor with Activity NBTI 5463 Is a Novel Bacterial Type II

T. Dougherty, M. Cronin, F. Reck, 2014 .

NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with Gram-6 negative antibacterial activity and in vivo efficacy

T. Dougherty, D. Ehmann, M. Cronin, 2014 .

Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

M. Huband, A. Marfat, T. Wisialowski, 2017, Bioorganic & medicinal chemistry letters.

In vitro activity of ceftazidime–avibactam and comparators against Gram-negative bacterial isolates collected in the Asia–Pacific region as part of the INFORM program (2015–2017)

W. Ko, G. Stone, 2020, Annals of Clinical Microbiology and Antimicrobials.

Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years with Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial.

Li-Min Huang, J. Bradley, E. Roilides, 2019, The Pediatric infectious disease journal.

In vitro activity of ceftazidime-avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018.

K. Kazmierczak, P. Kiratisin, G. Stone, 2021, Journal of global antimicrobial resistance.

The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment.

P. Bradford, G. Stone, W. Nichols, 2023, The Journal of antimicrobial chemotherapy.

Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.

A. Gales, D. Sahm, M. Wise, 2023, The Journal of antimicrobial chemotherapy.

PCR-RFLP typing of ureC from Helicobacter pylori isolated in Argentina from gastric biopsies before and after treatment with clarithromycin

D. Shortridge, R. Flamm, D. Stamler, 1997, Epidemiology and Infection.

Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro

R. Bonomo, R. Pandey, L. Glaser, 2019, mBio.

Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 μg/mL), a Novel β-Lactam/β-Lactamase Inhibitor Combination

M. Castanheira, M. Huband, H. Sader, 2023, Journal of clinical microbiology.

In Vitro Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program

M. Hackel, J. Karlowsky, D. Sahm, 2023, Antimicrobial agents and chemotherapy.

In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016–2018)

D. Piérard, G. Stone, 2021, BMC Infectious Diseases.

The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus.

G. Sensabaugh, F. DeLeo, B. Diep, 2008, The Journal of infectious diseases.

Antimicrobial Activity of Ceftazidime-Avibactam and Comparators Against Fluoroquinolone-Resistant Klebsiella pneumoniae Collected Globally from Antimicrobial Testing Leadership and Surveillance: 2018-2019.

P. Kiratisin, F. Arhin, G. Stone, 2022, Microbial drug resistance.